Fosaprepitant
 | |
 | |
| Systematic (IUPAC) name | |
|---|---|
|
[3-{[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl] ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl}-5-oxo- 2H-1,2,4-triazol-1-yl]phosphonic acid | |
| Clinical data | |
| AHFS/Drugs.com | Multum Consumer Information |
| MedlinePlus | a604003 |
| Licence data |
|
| Pregnancy category |
|
| Legal status | |
| Routes of administration | Intravenous |
| Pharmacokinetic data | |
| Bioavailability | n/a |
| Protein binding | >95% (aprepitant) |
| Metabolism | To aprepitant |
| Biological half-life | 9 to 13 hours (aprepitant) |
| Identifiers | |
| CAS Number |
172673-20-0  265121-04-8 (dimeglumine) |
| ATC code | A04AD12 |
| PubChem | CID 219090 |
| IUPHAR/BPS | 7623 |
| DrugBank |
DB06717  |
| ChemSpider | 189912 |
| UNII |
6L8OF9XRDC |
| KEGG |
D06597 |
| ChEBI | CHEBI:64321 |
| ChEMBL |
CHEMBL1199324 |
| Chemical data | |
| Formula | C23H22F7N4O6P |
| Molar mass | 614.406 g/mol |
| |
| |
| (what is this?) (verify) | |
Fosaprepitant (Emend for Injection (US), Ivemend (EU)) is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant.
Fosaprepitant was developed by Merck & Co. and was approved by the United States Food and Drug Administration (FDA) on January 25, 2008[1] and by the European Medicines Agency (EMA) on January 11 of the same year.[2]
See also
References
- ↑ "Drugs.com, FDA Approves Emend (fosaprepitant dimeglumine) for Injection, Merck's New Intravenous Therapy, for Use in Combination with Other Antiemetics for Prevention of Nausea and Vomiting Caused by Chemotherapy". Retrieved 2008-03-15.
- ↑ "European Public Assessment Report for Ivemend (from the EMEA website)". Retrieved 2008-03-15.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia - version of the Friday, February 26, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.